Background/Aims Cirrhosis is the most important risk factor of hepatocellular carcinoma (HCC), and patients with cirrhosis are recommended to receive semiannual surveillance for early HCC detection. However, early cirrhosis is often asymptomatic and can go undiagnosed for years, leading to underuse of HCC surveillance in clinical practice. We characterized the frequency and associated factors of unrecognized cirrhosis in a national sample of patients with HCC from the United States.
Methods HCC patients aged 68 years and older, diagnosed during 2011 to 2015 were included from the SEERMedicare Linked Database. If cirrhosis was diagnosed within 6 months immediately preceding HCC diagnosis or after HCC diagnosis, cases were categorized as unrecognized cirrhosis. Factors associated with unrecognized cirrhosis were identified using logistic regression analyses. Factors associated with overall survival were evaluated using Cox regression analyses.
Results Among 5,098 HCC patients, 74.8% patients had cirrhosis. Among those with cirrhosis, 57.4% had unrecognized cirrhosis, with the highest proportion (76.3%) among those with NAFLD-related HCC. Male sex (aOR: 2.12, 95% CI: 1.83–2.46), non-Hispanic Black race (aOR: 1.93, 95% CI: 1.45–2.57), and NAFLD etiology (aOR: 4.46, 95% CI: 3.68–5.41) were associated with having unrecognized cirrhosis. Among NAFLD-related HCC patients, male sex (aOR: 2.32, 95% CI: 1.71–3.14) was associated with unrecognized cirrhosis. Unrecognized cirrhosis was independently associated with worse overall survival (aHR: 1.17, 95% CI: 1.08–1.27) compared to recognized cirrhosis.
Conclusions Unrecognized cirrhosis is common in NAFLD-related HCC, particularly among male and Black patients, highlighting these groups as important intervention targets to improve HCC surveillance uptake and outcomes.
Citations
Citations to this article as recorded by
Disentangling the Effect of BMI on Hepatocellular Carcinoma From Cirrhosis With Multivariable Mendelian Randomization Apostolos Gkatzionis, Eleanor Sanderson, George Davey Smith, Stefan Stender, Helene Gellert‐Kristensen Liver International.2026;[Epub] CrossRef
Access to Evaluation for Liver Transplantation in the Veterans Health Administration Vera Yakovchenko, Michael F. Chang, Ruben Hernaez, Joseph A. Awad, Jennifer Anwar, Anna Nobbe, Heather McCurdy, Pratima Sharma, Patrick Spoutz, Manimegalai Murugavel, Mark A. Wilson, Jason A. Dominitz, Heather M. Patton, Megan A. Adams, Timothy R. Morgan, Digestive Diseases and Sciences.2025; 70(2): 552. CrossRef
Reply to: “A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?” Moon Haeng Hur, Jeong-Hoon Lee Journal of Hepatology.2025; 82(3): e143. CrossRef
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2025; 31(Suppl): S228. CrossRef
Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation Federico Carbone, Jean‐Pierre Després, John P. A. Ioannidis, Ian J. Neeland, Gabriella Garruti, Luca Busetto, Luca Liberale, Stefano Ministrini, Gemma Vilahur, Thomas H. Schindler, Maria Paula Macedo, Agostino Di Ciaula, Marcin Krawczyk, Andreas Geier, Gy European Journal of Clinical Investigation.2025;[Epub] CrossRef
Exploring the factors affecting the occurrence of postoperative MVI and the prognosis of hepatocellular carcinoma patients treated with hepatectomy: A multicenter retrospective study Jilin Yang, Junlin Qian, Zhao Wu, Wenjian Zhang, Zexin Yin, Wei Shen, Kun He, Yongzhu He, Liping Liu Cancer Medicine.2024;[Epub] CrossRef
Risk factors associated with late hepatocellular carcinoma detection in patients undergoing regular surveillance Sangmi Jang, Young-Joo Jin, Jin-Woo Lee, Dam Kwon, Jung Hwan Yu Medicine.2023; 102(32): e34637. CrossRef
SF3B4 stabilizes SREBF1 via 3′UTR binding to drive hepatocellular carcinoma progression Yuan Fang, Dan Wang, Lei Han, Mengge Li, Qiuyue He, WangGan Xu, HaiJing Li, Zhong Zeng, Jie Lin, HanFei Huang Frontiers in Oncology.2026;[Epub] CrossRef
METTL1-driven nucleotide metabolism reprograms the immune microenvironment in hepatocellular carcinoma: a multi-omics approach for prognostic biomarker discovery Xie Weng, Yangyue Huang, Zhuoya Fu, Xingli Liu, Fuli Xie, Jiale Wang, Qiaohua Zhu, Dayong Zheng Frontiers in Immunology.2025;[Epub] CrossRef
Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease” Won Sohn, Yong-Han Paik Clinical and Molecular Hepatology.2023; 29(1): 182. CrossRef
Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap Shen-Yung Wang Clinical and Molecular Hepatology.2023; 29(2): 349. CrossRef
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea? Min Kyung Park, Yoon Jun Kim Clinical and Molecular Hepatology.2023; 29(2): 332. CrossRef
The prime time for management of hepatocellular carcinoma in Hong Kong Landon L. Chan, Stephen L. Chan Clinical and Molecular Hepatology.2023; 29(2): 345. CrossRef
Regular Alpha-Fetoprotein Tests Boost Curative Treatment and Survival for Hepatocellular Carcinoma Patients in an Endemic Area Joo Hyun Oh, Jonghyun Lee, Eileen L. Yoon, Soung Won Jeong, Soon Sun Kim, Young Eun Chon, Sang Bong Ahn, Dae Won Jun Cancers.2023; 16(1): 150. CrossRef
First
Prev
